Fed Study of (Parlodel®) Bromocriptine Mesylate Capsules 5 mg
Status:
Completed
Trial end date:
2007-06-01
Target enrollment:
Participant gender:
Summary
The objective of this study was to assess the single-dose relative bioavailability of Mylan
Pharmaceuticals Inc. and Novartis Pharmaceuticals Corporation (Parlodel®) 5 mg bromocriptine
mesylate capsules, following the administration of a 10 mg dose, under fed conditions.